Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Lipocine Inc. (LPCN : NSDQ)

• Company Description    Lipocine, Inc. is a specialty pharmaceutical company. It develops pharmaceutical products for use in men's and women's health. The Company's lead product candidate, LPCN 1021, is in Phase 3 and is targeted to treat symptoms of low testosterone for men in need of testosterone replacement therapy. Its additional pipeline candidates include LPCN 1111, a next generation oral testosterone therapy product, and LPCN 1107, indicated for the prevention of preterm birth and is currently in Phase 1. Lipocine Inc. is headquartered in Salt Lake City, Utah. Number of Employees: 16

• Price / Volume Information    Yesterday's Closing Price: $2.54 Daily Weekly Monthly 20 Day Moving Average: 33,620 shares Shares Outstanding: 5.55 (millions) Market Capitalization: $14.10 (millions) Beta: 1.25 52 Week High: $5.93 52 Week Low: $2.52 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -18.07% -20.21% 12 Week -16.09% -19.57% Year To Date -47.95% -54.50%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 675 ARAPEEN DRIVE SUITE 202 - SALT LAKE CITY,UT 84108 USA ph: 801-994-7383 fax: 801-994-7388 pkelleher@lifesciadvisors.com http://www.lipocine.com

• General Corporate Information    Officers Mahesh V. Patel - President and Chief Executive Officer and Chief Fi Spyros Papapetropoulos - Chairman of the Board and Director Jeffrey Fink - Director Jill M. Jene - Director John Higuchi - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 53630X203 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/12/26 Share - Related Items Shares Outstanding: 5.55 Most Recent Split Date: 5.00 (0.06:1) Beta: 1.25 Market Capitalization: $14.10 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.55 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.87 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.97 Price/Cash Flow: - Price / Sales: 3.26 EPS Growth vs. Year Ago Period: -34.09% vs. Previous Quarter: -43.90% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -81.54% ROE 09/30/25 - -30.65 06/30/25 - -23.59 03/31/25 - -26.68 ROA 09/30/25 - -28.20 06/30/25 - -21.91 03/31/25 - -24.77 Current Ratio 09/30/25 - 8.25 06/30/25 - 12.71 03/31/25 - 15.64 Quick Ratio 09/30/25 - 8.25 06/30/25 - 12.71 03/31/25 - 15.64 Operating Margin 09/30/25 - -126.67 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - -126.67 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - -126.67 06/30/25 - -107.13 03/31/25 - -146.12 Book Value 09/30/25 - 2.61 06/30/25 - 3.20 03/31/25 - 3.59 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©